4.6 Review

Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5

期刊

AMERICAN JOURNAL OF PSYCHIATRY
卷 169, 期 5, 页码 465-475

出版社

AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2012.11081302

关键词

-

资金

  1. Shire
  2. Canadian Institutes of Health Research
  3. APA
  4. GlaxoSmithKline
  5. Eli Lilly
  6. NIMH
  7. National Institute on Drug Abuse
  8. Medical Research Council [G0801418B] Funding Source: researchfish

向作者/读者索取更多资源

Premenstrual dysphoric disorder, which affects 2%-5% of premenopausal women, was included in Appendix B of DSMIV, Criterion Sets and Axes Provided for Further Study. Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on premenstrual dysphoric disorder and provide recommendations regarding the appropriate criteria and placement for the disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据